Aurora Cannabis Inc. (ACB) Income Statement Analysis

See more : Molson Coors Beverage Company (0K2K.L) Income Statement Analysis – Financial Results

Complete financial analysis of Aurora Cannabis Inc. (ACB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aurora Cannabis Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Madhav Marbles and Granites Limited (MADHAV.NS) Income Statement Analysis – Financial Results
Jet.AI Inc. (JTAIZ) Income Statement Analysis – Financial Results
Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ) Income Statement Analysis – Financial Results
Alchemy Resources Limited (ALY.AX) Income Statement Analysis – Financial Results
Galecto, Inc. (GLTO) Income Statement Analysis – Financial Results

Aurora Cannabis Inc. (ACB)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.auroramj.com

About Aurora Cannabis Inc.

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	270.28M	233.29M	221.34M	245.25M	278.91M	247.94M	55.20M	18.07M	1.44M	0.00	0.00	0.00	0.00	0.00	0.00	40.83K	0.00	0.00
Cost of Revenue	138.82M	297.65M	200.11M	266.81M	312.45M	88.12M	11.68M	2.01M	763.00K	304.80K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	131.46M	-64.36M	21.23M	-21.56M	-33.54M	159.82M	43.52M	16.06M	676.27K	-304.80K	0.00	0.00	0.00	0.00	0.00	40.83K	0.00	0.00
Gross Profit Ratio	48.64%	-27.59%	9.59%	-8.79%	-12.03%	64.46%	78.84%	88.87%	46.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%
Research & Development	3.57M	6.56M	10.39M	11.45M	26.07M	14.78M	1.68M	314.00K	565.14K	432.38K	307.93K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	104.94M	68.22M	126.97M	139.68M	265.18M	279.40M	80.42M	14.40M	3.93M	2.61M	280.67K	152.64K	250.02K	181.96K	49.99K	185.35K	0.00	0.00
Selling & Marketing	51.94M	51.97M	62.03M	55.20M	91.27M	99.29M	29.45M	10.27M	1.71M	1.02M	248.21K	142.94K	61.27K	18.97K	7.20K	0.00	0.00	0.00
SG&A	156.88M	183.40M	188.99M	194.88M	356.45M	378.69M	109.86M	24.67M	5.63M	3.63M	280.67K	295.59K	311.29K	200.93K	57.18K	185.35K	228.56K	1.25K
Other Expenses	1.67M	0.00	-21.59M	6.13M	-28.64M	-3.26M	-907.00K	-1.14M	593.22K	-5.06M	25.82K	107.29K	19.50K	409.00	583.00	834.00	490.00	0.00
Operating Expenses	158.54M	189.96M	240.60M	225.09M	450.93M	456.84M	123.63M	25.70M	6.79M	4.37M	306.49K	402.88K	330.79K	201.33K	57.77K	186.18K	229.05K	1.25K
Cost & Expenses	297.36M	487.61M	440.71M	491.90M	763.38M	544.97M	135.30M	27.71M	6.03M	4.37M	306.49K	402.88K	330.79K	201.33K	57.77K	186.18K	229.05K	1.25K
Interest Income	12.81M	19.00M	4.51M	5.75M	4.99M	3.68M	2.51M	861.00K	72.78K	27.64K	7.86K	9.39K	15.03K	15.56K	14.35K	40.83K	0.00	0.00
Interest Expense	14.19M	39.46M	71.81M	66.44M	77.54M	41.03M	2.28M	1.29M	619.12K	177.41K	101.08K	9.39K	15.03K	745.00	484.00	310.00	0.00	0.00
Depreciation & Amortization	33.07M	43.57M	93.66M	98.08M	114.89M	88.26M	12.26M	1.09M	593.22K	304.80K	303.00	432.00	422.00	409.00	583.00	834.00	490.00	0.00
EBITDA	20.47M	-210.74M	-143.09M	-137.20M	-393.23M	-214.66M	-78.46M	-12.98M	-4.75M	-9.24M	-298.33K	-402.45K	-330.36K	-185.36K	-57.18K	-144.52K	-228.56K	-1.25K
EBITDA Ratio	7.58%	-90.34%	-64.65%	-55.94%	-140.99%	-86.58%	-142.14%	-71.86%	-329.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-353.91%	0.00%	0.00%
Operating Income	-46.45M	-254.32M	-231.45M	-282.82M	-490.96M	-314.24M	-95.77M	-11.19M	-4.59M	-4.37M	-306.49K	-402.88K	-330.79K	-202.08K	-58.25K	-145.35K	-229.05K	-1.25K
Operating Income Ratio	-17.19%	-109.01%	-104.57%	-115.32%	-176.03%	-126.74%	-173.51%	-61.95%	-318.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-355.95%	0.00%	0.00%
Total Other Income/Expenses	-31.15M	-41.10M	-1.43B	-392.46M	-2.83B	6.14M	168.08M	-1.90M	89.08K	-5.06M	-93.22K	9.39K	15.03K	-167.26K	0.00	0.00	0.00	0.00
Income Before Tax	-59.60M	-295.42M	-1.72B	-699.80M	-3.38B	-328.23M	77.33M	-17.26M	-5.87M	-9.73M	-399.71K	-393.49K	-315.76K	-353.77K	0.00	0.00	0.00	0.00
Income Before Tax Ratio	-22.05%	-126.63%	-777.14%	-285.34%	-1,213.27%	-132.38%	140.09%	-95.56%	-408.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-554.00K	-20.32M	-2.14M	-6.32M	-83.40M	-30.31M	8.10M	-4.30M	-148.84K	-207.71K	7.86K	0.00	0.00	-31.28K	-13.86K	310.00	-51.76K	-1.27K
Net Income	-69.33M	-265.33M	-1.72B	-693.63M	-3.31B	-290.84M	71.94M	-12.97M	-5.72M	-9.52M	-399.71K	-393.49K	-315.76K	-322.50K	-43.91K	-145.66K	-177.29K	1.27K
Net Income Ratio	-25.65%	-113.73%	-776.02%	-282.82%	-1,186.90%	-117.30%	130.33%	-71.78%	-397.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-356.71%	0.00%	0.00%
EPS	-1.46	-8.22	-7.99	-41.01	-342.14	-435.59	1.88	-0.56	-0.53	-1.48	-0.30	-0.29	-0.24	-0.24	-0.04	-0.12	-0.19	0.01
EPS Diluted	-1.46	-8.22	-7.99	-41.01	-342.14	-435.59	1.83	-0.56	-0.53	-1.48	-0.30	-0.29	-0.24	-0.24	-0.04	-0.12	-0.19	0.01
Weighted Avg Shares Out	47.42M	32.27M	214.91M	16.91M	9.68M	667.69K	38.32M	23.25M	10.75M	6.41M	1.35M	1.34M	1.32M	1.32M	1.23M	1.20M	935.16K	162.85K
Weighted Avg Shares Out (Dil)	47.42M	32.27M	214.91M	16.91M	9.68M	667.69K	39.28M	23.25M	10.75M	6.41M	1.35M	1.34M	1.32M	1.32M	1.23M	1.20M	935.16K	162.85K

Prediction: Aurora Cannabis Will Be Worth More Than Canopy Growth in 5 Years

August 24, 2024fool.com

Aurora Cannabis and Canopy Growth have been leading companies within the cannabis industry for years. Both businesses have struggled, however, and have been working on improving their financials.

Aurora Cannabis Had a Strong Q1, but Investors Should Expect a Slowdown in Future Quarters

August 16, 2024fool.com

Aurora Cannabis has made significant strides in improving its financials. The company generated positive free cash flow and revenue rose last quarter.

Cannabis MSOs embrace new markets, streamline operations in Q2

August 13, 2024proactiveinvestors.com

Earnings from North American cannabis companies for the second quarter have been a mixed bag, with expansion into new markets, operational streamlining, and product innovation key themes across the sector. Many multi-state operations (MSOs) are turning to emerging, less saturated...

Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

August 12, 2024prnewswire.com

NASDAQ | TSX: ACB EDMONTON, AB , Aug. 12, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General...

The Cannabis Sector: Profitability Takes Center Stage

August 9, 2024marketbeat.com

The cannabis industry has experienced significant change since its inception twelve years ago. Fueled by legalization trends and evolving social acceptance, this burgeoning sector has attracted considerable investment and innovation.

Aurora Cannabis: Revving Up To Profitability

August 8, 2024seekingalpha.com

Aurora Cannabis achieves milestone positive free cash flow for the first time in Q1 FY2025. Strong growth in medical cannabis, particularly in Australia and Europe, positions the company well for future profitability. Potential US rescheduling of cannabis could impact Aurora's...